Mutations in numerous genes encoding ribosomal proteins (RPs) occur in 50%-70% of individuals with Diamond-Blackfan anemia (DBA), establishing the disease as a ribosomopathy. As described in this issue of JCI, Sankaran, Gazda, and colleagues used genome-wide exome sequencing to study DBA patients with no detectable mutations in RP genes. They identified two unrelated pedigrees in which the disease is associated with mutations in GATA1, which encodes an essential hematopoietic transcription factor with no known mechanistic links to ribosomes. These findings ignite an interesting and potentially emotional debate on how we define DBA and whether the term should be restricted to pure ribosomopathies. More generally, the work reflects the powerful knowledge and controversies arising from the deluge of data generated by new genetic technologies that are being used to analyze human diseases.
. Positional cloning revealed that the mutated gene was RPS19, which encodes a protein component of the small 40S ribosomal subunit (3). Subsequently, RPS19 mutations were identified in approximately 25% of DBA families, all of which showed dominant inheritance. Speculation about how RPS19 mutations might cause DBA ensued for about 10 years. Specifically, it was debated as to whether the disease results from loss of unique extraribosomal activities of RPS19 or through impaired ribosome production. Support for the latter hypothesis emerged when a flurry of other DBA genes were identified, all of which encoded different small or large ribosomal subunit proteins (RPs) (4).
GATA-1, a zinc finger transcription factor expressed mainly in blood cell precursors, is essential for the development of red blood cells, megakaryocytes and their platelet progeny, mast cells, and eosinophils (10) . Several human blood disorders are caused by GATA1 mutations that partially reduce and/or alter function of the corresponding protein (ref. 11 and Figure 2 ). Germline misthe X chromosome-encoded GATA1 gene. By targeted sequencing of an additional 62 male DBA patients, all negative for RP gene mutations, they identified a second family with an independent GATA1 gene mutation. Both of these mutations alter mRNA splicing to favor the production of an amino-truncated GATA-1 protein termed GATA-1 short, or GATA-1s.
10 RP genes (4, 5) . Additional diseases in which causative mutations impair ribosomes include the inherited Treacher-Collins and Shwachman-Diamond syndromes and 5q-myelodysplastic syndrome, caused by a somatic chromosomal deletion (4) . These disorders illustrate the concept that genetic alterations in basic cellular pathways can produce unique combinations of organ-specific pathologies. How ribosome disruptions lead to DBA is not understood, but a popular theory is that imbalances in individual RPs trigger a p53-mediated checkpoint leading to cell cycle arrest and apoptosis of erythroid precursors (4). In support, certain RPs bind to and inhibit the p53 regulator MDM2 (6) . Moreover, in animal models, the DBA-like effects of RP mutations depend in part on p53 (refs. 7, 8, and Figure 1 ).
GATA1 gene mutations in patients diagnosed with DBA Sankaran and colleagues used genomewide exome sequencing to analyze most or all transcribed genes in two brothers without an apparent mutation in any RP gene (9) . Both patients harbored a mutation in disposition, and abnormalities in organogenesis, is caused by mutations in at least 15 distinct genes that interact to sense and repair DNA cross-links (15) . Indeed, verifying that candidate proteins function in this DNA repair pathway has strengthened the identification of new FA genes. Analogously, it is predicted that new DBA genes will somehow participate in ribosome biology. This raises the interesting question of whether ribosomes and GATA-1 are functionally linked. Both DBA and loss of GATA-1 induce apoptosis of erythroid precursors (16, 17) . Through direct and indirect transcriptional actions, GATA-1 inhibits the expression of proapoptotic proteins and promotes the expression of antiapoptotic ones (18) . Moreover GATA-1 binds p53 directly to inhibit its apoptotic activities (19) . Thus, GATA-1 and ribosome biosynthesis may intersect through their abilities to control erythroid apoptotic regulators. In addition, ribosome dysfunction could selectively affect the translation of specific mRNAs, altering the proteome with particularly deleterious consequences in erythroid cells. Through this mechanism, it is possible that mutations in RP subunit genes somehow impair the expression of GATA-1 and/or its cofactors. Alternatively, it is possible that GATA-1 and ribosome functions are not directly linked and that two independent pathways cause the same phenotype. Other inherited disorders, for example hereditary deafness, retinitis pigmentosa, and VACTERL/ VATER association, are genetically heterogeneous, each with causative mutations in genes affecting diverse functional pathways. Complicating the issue, similar or identical GATA1 mutations can produce varying clinical manifestations in different individuals (Figure 3) , explaining in part why the patients described by Sankaran et al. were diagnosed with DBA, whereas the family described by Hollanda et al. carries the diagnosis of "congenital anemia with trilineage dysplasia" (13).
What's in a name?
Categorizing inherited disorders according to conventional nomenclature provides rich historical perspective and an important contextual framework in which to classify clinical phenotypes. However, it is now obvious that one "disease" as defined clinically can have multiple genetic etiologies with unique implications for prognosis and medical management. For example, identification of an X-linked causal
The controversy
While DBA is phenotypically and genetically heterogeneous, a pathogenic mutation in an RP subunit gene usually consolidates the clinical diagnosis. In individuals without RP gene mutations, the diagnosis is based purely on clinical findings after a variety of other conditions that cause erythroid hypoplasia are excluded (14) . The patients described by Sankaran et al. received their clinical diagnosis from DBA experts according to current consensus guidelines. Moreover, mutations in GATA1 and RP genes clearly produce overlapping phenotypes (Figure 3 ). These findings raise the question of whether GATA1 should be included as a new "DBA gene." Alternatively, should GATA1 gene mutations be excluded before a clinical diagnosis of DBA is made? Both views have their justifications, shortcomings, and precedence in the nomenclature of human disease. Suddenly becoming "not DBA" or a "different type of DBA" through new genetic testing can unsettle patients and physicians when a diagnosis that they have come to accept potentially unravels.
Medical syndromes are typically defined by signature constellations of physical and laboratory findings. Most were named years ago according to clinical features (e.g., dyskeratosis congenita) or after physicians who first described them (e.g., DBA or Fanconi anemia [FA] ). More recently, molecular studies have revealed that many of these syndromes are genetically heterogeneous, with causative mutations occurring in one of multiple genes that function in a common pathway, thereby explaining the shared clinical phenotype. For example, FA, a bone marrow failure syndrome characterized by hypoplasia of all blood cell precursors (aplastic anemia), cancer presense mutations that alter the amino-terminal (NH 2 ) zinc finger motif of GATA-1 protein can impair DNA binding and/or cofactor interactions. Clinical phenotypes associated with such mutations include anemia and/or thrombocytopenia, platelet dysfunction, porphyria (disrupted heme synthesis), and thalassemia (imbalanced globin chain synthesis). Another class of clinically important GATA1 mutations occur in exon 2 or surrounding introns and lead to the production of GATA-1s, which lacks amino acids 1-83. This region is termed the NH 2 -terminal activation domain (NAD), by virtue of its ability to activate transcription in non-erythroid cells. The NAD binds the retinoblastoma tumor suppressor protein, which may regulate the capacity of GATA-1 to control cell survival or proliferation (12) . Somatic mutations leading to the predominant production of GATA-1s are invariably associated with transient myeloproliferative disorder (a preleukemia) and acute megakaryoblastic leukemia in young children with Down syndrome (10). Sankaran et al. (9) identified two different DBA-associated germline GATA1 mutations, both at the end of exon 2. These mutations alter mRNA splicing to favor GATA-1s production. While not formally proven, it is highly likely that the anemia in these patients is caused by GATA1 mutations. Complicating matters, one of the mutations was described previously in a Brazilian pedigree with affected males exhibiting congenital anemia, neutropenia, and trilineage dysplasia of blood precursors (13) . These patients were not diagnosed with DBA, although their clinical features overlapped with those of the patients described by Sankaran et al.
Figure 3
Shared and distinct phenotypes in congenital red cell aplasia caused by mutations in RP genes and in GATA1. eADA, erythrocyte adenosine deaminase activity, MCV, mean corpuscular volume; Hb, hemoglobin; TMD, transient myeloproliferative disorder.
mutation for congenital red cell aplasia or "DBA" in the current study provides important information for genetic counseling of affected families. Clearly, how we name diseases is less important than how we understand them. As diagnostic DNA sequencing becomes increasingly convenient and less expensive, it is more important than ever for practicing physicians to be aware of the clinical consequences of individual gene mutations, the limitations of current knowledge, and the fast-moving new insights that come our way with the advancing technologies of gene discovery.
